Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Decline in Short Interest

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 47,300 shares, a decline of 23.1% from the December 15th total of 61,500 shares. Based on an average daily volume of 122,300 shares, the short-interest ratio is currently 0.4 days.

Institutional Trading of Entera Bio

A hedge fund recently raised its stake in Entera Bio stock. Parkman Healthcare Partners LLC lifted its stake in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 2.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 411,076 shares of the company’s stock after acquiring an additional 9,558 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 1.15% of Entera Bio worth $781,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Price Performance

ENTX stock traded up $0.11 during mid-day trading on Friday, reaching $2.34. The company had a trading volume of 135,985 shares, compared to its average volume of 206,778. The stock has a 50 day simple moving average of $2.04 and a two-hundred day simple moving average of $1.87. The company has a market capitalization of $83.73 million, a price-to-earnings ratio of -9.00 and a beta of 1.49. Entera Bio has a 52 week low of $0.68 and a 52 week high of $3.35.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Entera Bio in a report on Monday, November 11th.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.